About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
University of Miami Sylvester Comprehensive Cancer Center
COVID-19
Videos
Lung
Lymphoma
Leukemia
2nd Biennial Miami Leukemia Symposium
AML Biology and Treatment
MDS Biology and Treatment
ALL Biology and Treatment
CLL Therapy in 2019
CML and MPNs: Final Frontiers and New Breakthroughs
Myeloid Biology and Novel Therapies
Events
AML Biology and Treatment
20:35
University of Miami's 2nd Biennial Miami Leukemia Symposium
Curing APL in 2020: Have We Completely Deciphered Mechanism(s) of Coagulopathy? Should Pts Be Treated Differently According to Their Bleeding Risk? Should We Revisit Heparin?
FEATURING
Martin Tallman
51 views
October 23, 2020
16:42
University of Miami's 2nd Biennial Miami Leukemia Symposium
IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of Resistance in R/R AML? What Are the Strategies to Combine IDH Inhibitors With SoC?
FEATURING
Eytan Stein
222 views
May 14, 2020
1
20:28
University of Miami's 2nd Biennial Miami Leukemia Symposium
Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding Assay Could Be Utilized to Select Patients That Are More Likely to Respond to Treatment With PUH71
FEATURING
Monica Guzman
12 views
May 14, 2020
23:05
University of Miami's 2nd Biennial Miami Leukemia Symposium
Venetoclax Can Effectively Target AML Stem Cells Through Acid-Fueled OXPHOS, AML M5 Is a Risk Factor for Lack of Response to Venetoclax
FEATURING
Daniel Pollyea
23 views
May 14, 2020